Read time: 2 minutes
By: McKesson Health Systems Editorial Team
Orphan drugs have been making headlines for decades — not only for bringing new treatment options to patients with rare conditions and diseases, but also for notoriously high costs that are rewriting the rules for pricing, discounts, and reimbursement.
With worldwide orphan drug sales growing more than twice as fast as non-orphan pharmaceuticals, both the opportunity of optimizing manufacturer discounts and the risk of figuratively leaving money on the table are too great for 340B health systems to ignore.
Read more about important strategies for navigating 340B to improve pricing on orphan drugs in McKesson’s latest article in collaboration with Becker’s Hospital Review here.
Click to learn how McKesson helps health systems achieve more.
Share
Post
Post
Email